Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021

Source avec lien : MMWR. Morbidity and Mortality Weekly Report, 70, . 10.15585/mmwr.mm7003e2

La transmissibilité accrue de la variante B.1.1.7 justifie une conformité universelle et accrue aux stratégies d’atténuation, y compris la distanciation et le masquage. Une couverture vaccinale plus élevée pourrait être nécessaire pour protéger le public. L’analyse des séquences génomiques par le biais du programme national de surveillance des souches du SRAS-CoV-2 permettra une approche ciblée pour identifier les variantes préoccupantes aux États-Unis.

What is already known about this topic? A more highly transmissible variant of SARS-CoV-2, B.1.1.7, has been detected in 10 U.S. states. What is added by this report? Modeling data indicate that B.1.1.7 has the potential to increase the U.S. pandemic trajectory in the coming months. CDC’s system for genomic surveillance and the effort to expand sequencing will increase the availability of timely U.S. genomic surveillance data. What are the implications for public health practice? The increased transmissibility of the B.1.1.7 variant warrants universal and increased compliance with mitigation strategies, including distancing and masking. Higher vaccination coverage might need to be achieved to protect the public. Genomic sequence analysis through the National SARS-CoV-2 Strain Surveillance program will enable a targeted approach to identifying variants of concern in the United States.

Lisez l’article

Laisser un commentaire